-
Biora Therapeutics NASDAQ:BIOR Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
Location: 4330 La Jolla Village Dr Ste 200, California, 92122, US | Website: www.progenity.com | Industry: Medical Laboratories | Sector: Health Care and Social Assistance
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
67.03M
Cash
5.325M
Avg Qtr Burn
-12.06M
Short % of Float
23.79%
Insider Ownership
0.60%
Institutional Own.
38.19%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BT-600 Details Inflammatory bowel disease, Ulcerative colitis | Phase 1b Initiation |